Outset Medical reported its Q2 2026 results alongside the announcement of a $40 million multi-year fleet refresh agreement with HCA, signaling solid demand visibility for its Tablo Hemodialysis System. However, recent FDA inspection observations underscore potential regulatory compliance risks that could affect manufacturing continuity and product availability. The company’s business model combines capital equipment sales to hospitals and clinics with recurring consumable revenue, a dynamic that depends heavily on installed base growth and customer renewals. Navigating these regulatory and operational factors while capitalizing on rising renal disease trends and adoption of home dialysis solutions will shape Outset’s path forward.